Google, Nvidia, and Microsoft eye biotech as the real AI moneymaker: Returns are high and AI’s hallucination is a benefit. The ventures could help subsidize the industry’s high costs.
Consumers have different views on public health threats: We examine why marketers must align their messaging to the hot-button health issues top of mind for patients.
HIMSS roundup—Big Tech pushes deeper into healthcare AI: A slew of firms are taking on healthcare AI, but they still need to address a huge challenge—trust.
Apple hypes up Vision Pro for healthcare: It’s getting healthcare apps for surgical assistance, medical education, and more. But most physicians are proceeding with caution—for now.
Microsoft’s demand for AI infrastructure sends Oracle’s shares soaring: Oracle’s affordability and healthcare moves last year, followed by AI investments in 2024, are set to grow its cloud presence.
Salesforce’s new AI tools will help doctors manage patient care: The offerings stack Salesforce against other Big Tech players with AI solutions for the healthcare industry.
Biden takes aim at the healthcare industry: We unpack his ambitious agenda and lay out what to look out for, and what’s motivating the proposals.
FDA clears the first OTC continuous glucose monitor: Dexcom wants to sell CGMs to diabetics—and maybe to non-diabetics, too. We explore the pros and cons of this latest direct-to-consumer healthcare trend.
How physicians are using social media: We unpack what pharma brands need to know about docs’ social usage—and how marketers can connect with them on various platforms.
Mark Cuban’s next pharma foray: The billionaire’s drug company is getting more creative in how it’s tackling medication shortages and high Rx prices.
Cigna unveils healthcare solutions at investor day: The programs address hot-button healthcare issues and highlight its Evernorth business, as the industry fends off DC scrutiny
On today's podcast episode, we discuss what happened when the first human ever received a brain implant from Neuralink, the other potential benefits of this technology outside of helping people with paralysis, and what the ultimate goal of Neuralink actually is. "In Other News," we talk about what happens now that ChatGPT has a memory and what to make of Gemini's rough start. Tune in to the discussion with our analysts Jacob Bourne and Gadjo Sevilla.
Patients saddled with large amounts of medical debt often don’t pay up: Healthcare providers’ collection rates could continue to worsen. We detail the reasons why—and explore how they can improve.
Virta Health’s approach to lower-cost weight loss should please employers, health plans: People who stopped taking expensive weight-loss drugs but stuck with a low-carb diet kept the weight off, a new study shows.
D2C pharmacies face challenges stocking costly drugs: But a new study suggests Amazon Pharmacy has an advantage over rivals.
Lots of consumers are self-medicating: A new survey discloses the many reasons patients give for taking meds without a doc’s supervision. Marketers must pay closer attention to the worrisome trends of self-medication and self-diagnosis.
Independent pharmacies are getting squeezed: Facing financial pressure, a third of community pharmacies say they’re considering closing down. We look at what this means for patients and the industry.
UnitedHealth Group is facing an antitrust investigation: The probe could rein in the most dominant US healthcare company.
Vale Health’s new online marketplace vets health and wellness solutions for patients: Healthcare brands with products on the platform could see increased sales—here’s why.
Pharma is moving slowly on AI adoption: A new survey shows the drug industry’s tentative approach to AI tech. We unpack the reasons for this lag and show where AI will be put to work—from marketing to clinical trials.